John Hohneker Net Worth

What's John Hohneker's mailing address?

John's mailing address filed with the SEC is 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON, MA, 02421.

Insiders trading at Humanigen

Over the last 5 years, insiders at Humanigen have traded over $2,588,252,690 worth of Humanigen stock and bought 2,107,496 units worth $5,417,461 . The most active insiders traders include Dale Cheval Holdings, Ltd.B..., Dale Black Horse Capital Ma... и Bay Ltd. Nomis. On average, Humanigen executives and independent directors trade stock every 34 days with the average trade being worth of $7,693. The most recent stock trade was executed by Dale Black Horse Capital Lp... on 18 October 2023, trading 386,350 units of HGEN stock currently worth $3,864.

What does Humanigen do?

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Humanigen executives and stock owners

Humanigen executives and other stock owners filed with the SEC include:

• Dr. Cameron Durrant M.B.A., M.D., MBA,
  Chairman & CEO
• Timothy E. Morris CPA, CPA,
  CFO & COO
• Timothy E. Morris CPA,
  CFO & COO
• Dr. Dale Chappell M.B.A., M.D., MBA,
  Chief Scientific Officer & Director
• Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H.,
  Chief Medical Officer
• Edward P. Jordan M.B.A.,
  Chief Commercial Officer
• Robert Atwill M.B.A.,
  Head of Asia-Pacific Region
• Dr. Omar Ahmed Pharm.D.,
  Sr. VP of Clinical, Medical & Scientific Affairs
• Dr. Tarek Sahmoud M.D., Ph.D.,
  Chief Medical Officer
• Kenneth Eugene Trbovich C.F.A.,
  Sr. VP of Investor Relations
• Bay Ltd. Nomis,
  10% owner
• Dale Chappell,
  Chief Scientific Officer
• Cheryl Buxton,
  
• Dale Cheval Holdings, Ltd.B...,
  
• Ronald Barliant,
  
• Edward P. Jordan,
  Chief Commercial Officer
• Cameron Durrant,
  Chief Executive Officer
• Rainer J. Boehm,
  
• Dale Black Horse Capital Ma...,
  Chief Scientific Officer
• Yili Kevin Xie,
  
• John Hohneker,
  
• Dale Cheval Holdings, Ltd.B...,
  Chief Scientific Officer
• Timothy E Morris,
  COO and CFO
• Dale Black Horse Capital Lp...,
  Chief Scientific Officer
• Dale Black Horse Capital Lp...,
  Chief Scientific Officer